Home › Calculator › SNPHY Dividend Calculator 2026
SNPHY DRIP Calculator & Dividend Yield 2026
2.03% YieldHealthcareSanten Pharmaceutical Co., Ltd. · OTC
Price: $11.19 · Annual div: $0.2270/share · Frequency: semi-annual · Payout ratio: N/A · Ex-div: 2026-09-29
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
SNPHY Dividend Yield
SNPHY (Santen Pharmaceutical Co., Ltd.) has a dividend yield of 2.03%, based on an annual dividend of $0.2270 per share and a price of $11.19. Over the last 12 months it paid $0.2270 per share — a trailing yield of 2.03%. Dividends are paid semi-annual.
Yield history: over the last 12 payments, SNPHY's 12-month yield ranged from 1.77% to 3.58%. Full SNPHY dividend history ↓
Yield on cost: if SNPHY's dividend keeps growing 8.0% a year, a purchase at today's price would yield 2.98% after 5 years, 4.38% after 10 years and 9.46% after 20 years on the original investment.
SNPHY DRIP Rate: How Many Shares Your Dividends Buy
With dividends reinvested, a SNPHY position grows its share count by about 2.02% in the first year at today's price and yield.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When SNPHY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
SNPHY Dividend History — Last 31 Payments
| Ex-Dividend Date | Payment Date | Amount / Share | TTM Yield | Stock Price |
|---|---|---|---|---|
| 2026-09-29Latest | 2026-11-30 | $0.1098 | 3.02% | $11.55 |
| 2026-03-31 | 2026-07-14 | $0.1172 | 2.16% | $11.05 |
| 2025-09-30 | 2025-12-08 | $0.1215 | 2.34% | $10.77 |
| 2025-03-31 | 2025-07-10 | $0.1301 | 2.63% | $9.25 |
| 2024-09-30 | 2024-12-16 | $0.1131 | 1.78% | $12.32 |
| 2024-03-28 | 2024-07-11 | $0.1057 | 3.19% | $10.15 |
| 2023-09-29 | 2023-12-15 | $0.1076 | 3.58% | $9.30 |
| 2023-03-31 | 2023-07-13 | $0.1106 | 3.04% | $7.42 |
| 2022-09-30 | 2022-12-15 | $0.1149 | 3.35% | $6.96 |
| 2022-03-30 | 2022-07-12 | $0.1181 | 2.36% | $10.98 |
| 2021-09-29 | 2021-12-15 | $0.1414 | 1.77% | $15.09 |
| 2021-03-30 | 2021-07-13 | $0.1262 | 1.85% | $14.09 |
| 2020-09-29 | 2020-12-15 | $0.1343 | — | — |
| 2020-03-30 | 2020-07-10 | $0.1304 | — | — |
| 2019-09-27 | 2019-12-16 | $0.1186 | — | — |
| 2019-03-29 | 2019-07-11 | $0.1206 | — | — |
| 2018-09-26 | 2018-12-17 | $0.0835 | — | — |
| 2018-03-27 | 2018-07-12 | $0.0859 | — | — |
| 2017-09-27 | 2017-11-01 | $0.0843 | — | — |
| 2017-03-28 | 2017-07-11 | $0.0849 | — | — |
| 2016-09-28 | 2016-12-15 | $0.1143 | — | — |
| 2016-03-29 | 2016-07-12 | $0.1275 | — | — |
| 2015-09-28 | 2015-12-15 | $0.0975 | — | — |
| 2015-03-29 | 2015-07-10 | $0.0969 | — | — |
| 2014-09-28 | 2014-12-15 | $0.0842 | — | — |
| 2014-03-27 | 2014-07-11 | $0.0982 | — | — |
| 2013-09-26 | 2013-12-16 | $0.0975 | — | — |
| 2013-03-27 | 2013-07-11 | $0.1019 | — | — |
| 2012-09-26 | 2012-12-17 | $0.1210 | — | — |
| 2012-03-28 | 2012-07-06 | $0.1247 | — | — |
| 2011-09-28 | 2011-12-15 | $0.1280 | — | — |
About Santen Pharmaceutical Co., Ltd. (SNPHY) — Dividend Analysis 2026
Santen Pharmaceutical Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and distribution of pharmaceuticals and medical devices, with operations spanning Japan and international markets. The company maintains a significant pipeline and array of products focused on ophthalmic conditions. For glaucoma and ocular hypertension, their drug candidates encompass DE-111, currently undergoing Phase III clinical evaluation; DE-117, which is available in Japan; DE-126, now in Phase IIb trials; DE-128, being developed for European markets and also in Phase II/III trials within the United States; and DE-130A, another compound advancing through Phase III clinical trials. Santen's development efforts also extend to treatments for other eye ailments: DE-114A for allergic conjunctivitis, DE-076C to address vernal keratoconjunctivitis, and DE-109, a therapy for uveitis that is in Phase III trials. Furthermore, their initiatives against myopia include DE-127, which is simultaneously in Phase II/III clinical trials in Japan and Phase III across Asia, alongside STN1013400, currently in its initial Phase I clinical trials for the same condition. They also offer DE-089C, a treatment for dry eye that has successfully completed its Phase III clinical trials. Beyond prescription medications, Santen also supplies a selection of over-the-counter pharmaceutical products. The corporation, founded in Osaka, Japan, in 1890, was initially known as Santendo Pharmaceutical Co., Ltd. before formally adopting its current name, Santen Pharmaceutical Co., Ltd., in 1958.
SNPHY Dividend & DRIP — Frequently Asked Questions
What is SNPHY's dividend yield?
SNPHY (Santen Pharmaceutical Co., Ltd.) has a dividend yield of 2.03%, based on an annual dividend of $0.2270 per share and a price of $11.19. Over the last 12 months it paid $0.2270 per share — a trailing yield of 2.03%. Dividends are paid semi-annual.
How much does $10,000 in SNPHY pay in dividends?
$10,000 in SNPHY at a 2.03% yield pays about $203 a year ($17 a month) before taxes. With DRIP, reinvested dividends buy more shares and that income compounds.
What is the DRIP rate for SNPHY?
With dividends reinvested, a SNPHY position grows its share count by about 2.02% in the first year at today's price and yield.
How do I calculate SNPHY dividend reinvestment (DRIP) returns?
Enter your starting amount, monthly contribution and time horizon in the SNPHY DRIP calculator at the top of this page. It reinvests each payout into new shares at the projected price, grows the dividend at the rate you choose and shows yearly income, share count, portfolio value and yield on cost. You can switch DRIP off to compare.
When is SNPHY's next ex-dividend date?
SNPHY's next ex-dividend date has not been announced yet; the most recent one was 2026-09-29. SNPHY pays dividends semi-annual. Buy before the ex-dividend date to receive the next payment.
What is SNPHY's dividend growth rate?
SNPHY's dividend changed -9.8% over the last year and 7.9% a year on average over five years.
Similar dividend stocks to SNPHY
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full SNPHY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SNPHY position with:
🌍 SNPHY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold SNPHY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.03% | -0.77% | $203 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1.73% | -1.07% | $173 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1.62% | -1.18% | $162 / yr |
| 🇬🇧 UK ISA | 0% | 2.03% | -0.77% | $203 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1.85% | -0.95% | $185 / yr |
| 🇨🇦 TFSA | 0% | 2.03% | -0.77% | $203 / yr |
| 🇨🇦 CA Taxable | 25% | 1.52% | -1.28% | $152 / yr |
| 🇦🇺 Super (pension) | 15% | 1.73% | -1.07% | $173 / yr |
| 🇦🇺 AU Taxable | 30% | 1.42% | -1.38% | $142 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.49% | -1.31% | $149 / yr |
| 🇫🇷 FR Taxable | 30% | 1.42% | -1.38% | $142 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 SNPHY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.23/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 SNPHY Dividend Payment Schedule
SNPHY pays quarterly — 4 times per year. Ex-div: 2026-09-29.
📊 SNPHY vs Healthcare Benchmarks
How SNPHY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SNPHY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ SNPHY Insider Activity
No recent SEC filings reported in the last 90 days.Peer Group
Similar companies in the same sectorCompare SNPHY with peers: SNPHY vs BLCO · SNPHY vs EYPT · SNPHY vs KOD
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SNPHY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Santen Pharmaceutical Co., Ltd. (SNPHY) is currently trading at $11.19, 20% below its 52-week high. The current dividend yield is 2.03% based on an annual payout of $0.2270 per share.
SNPHY (Santen Pharmaceutical Co., Ltd.) — 2.03% Dividend Yield Analysis
Santen Pharmaceutical Co., Ltd. (SNPHY) is a healthcare stock currently trading at $11.19 with a dividend yield of 2.03%. It pays an annual dividend of $0.2270 per share. Over the past 5 years, SNPHY has grown its dividend at a compound annual rate of 7.9%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest SNPHY News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.
How investors use the SNPHY dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.